Evidence map›Paper›PMID 40987979›Full record

ReviewInflammopharmacology2025

Resveratrol: potential therapeutic effects on ocular health.

Bennett Kurien Biju, Marina Andavar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bennett Kurien BijuDepartment of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, 603 203, India.
Marina AndavarDepartment of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, 603 203, India. marinaa@srmist.edu.in.ORCID http://orcid.org/0000-0003-3555-5420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol, a polyphenolic compound predominantly found in grapes and red wine, exhibits significant biological activity due to its potent antioxidant and anti-inflammatory properties. Known for its cardioprotective, chemotherapeutic, neuroprotective, and anti-aging effects, resveratrol has garnered attention for its potential in managing age-related ocular diseases, such as glaucoma, cataract, diabetic retinopathy, and macular degeneration-conditions, where oxidative stress and inflammation play central roles in disease progression and vision impairment. Both in vitro and animal studies indicate that resveratrol impacts key biological pathways, including oxidative stress modulation, inflammation reduction, mitochondrial protection, apoptosis regulation, and angiogenesis suppression, which are implicated in the pathology of these ocular conditions. Resveratrol with antioxidant, anti-inflammatory, and anti-angiogenic properties, shows promise in treating ophthalmic diseases by targeting oxidative stress and abnormal angiogenesis, offering a safer, non-invasive alternative to conventional drugs and better scientific validation than herbal remedies. This review synthesizes current research on resveratrol's mechanisms of action, therapeutic potential, and limitations as a treatment for eye disorders, highlighting its promise as a nutritional intervention and areas requiring further exploration.

Indexed as

Eye DiseasesResveratrolStilbenesAnimalsAnti-Inflammatory AgentsAntioxidantsHumansInflammationOxidative StressAnti-Inflammatory AgentsAntioxidantsResveratrolStilbenesAge-related macular degenerationCataractDiabetic retinopathyEye healthGlaucomaOcular diseasePhytochemicals

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.